Daré Bioscience reports Phase 1 study shows topical sildenafil cream cuts systemic exposure versus oral dose
DARE•Lower systemic exposure than oral sildenafil
The study showed substantially lower systemic exposure with topical dosing versus oral sildenafil, supporting a localized delivery profile.
Treatments were generally well tolerated, with only mild adverse events reported and no serious safety signals.
Development continues in women’s sexual health
The data underpin continued development for women’s sexual health, including a dose later used in a Phase 2b study in women.
Phase 1 results published for topical sildenafil cream
Daré Bioscience reported peer-reviewed publication of Phase 1 results for topical Sildenafil Cream, 3.6% in healthy men.
The results were already presented via the journal article in Sexual Medicine.
